AR052266A1 - Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos - Google Patents

Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos

Info

Publication number
AR052266A1
AR052266A1 ARP050105197A ARP050105197A AR052266A1 AR 052266 A1 AR052266 A1 AR 052266A1 AR P050105197 A ARP050105197 A AR P050105197A AR P050105197 A ARP050105197 A AR P050105197A AR 052266 A1 AR052266 A1 AR 052266A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
group
atoms
membered heterocyclic
Prior art date
Application number
ARP050105197A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34090028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR052266A1 publication Critical patent/AR052266A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
ARP050105197A 2004-12-14 2005-12-12 Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos AR052266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0427381.9A GB0427381D0 (en) 2004-12-14 2004-12-14 Organic compounds

Publications (1)

Publication Number Publication Date
AR052266A1 true AR052266A1 (es) 2007-03-07

Family

ID=34090028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105197A AR052266A1 (es) 2004-12-14 2005-12-12 Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos

Country Status (21)

Country Link
US (1) US20100087432A1 (enExample)
EP (1) EP1828172B1 (enExample)
JP (1) JP2008523130A (enExample)
KR (1) KR20070087605A (enExample)
CN (1) CN101072773B (enExample)
AR (1) AR052266A1 (enExample)
AT (1) ATE449772T1 (enExample)
AU (1) AU2005315881C1 (enExample)
BR (1) BRPI0518607A2 (enExample)
CA (1) CA2587934A1 (enExample)
DE (1) DE602005017935D1 (enExample)
ES (1) ES2335519T3 (enExample)
GB (1) GB0427381D0 (enExample)
GT (1) GT200500360A (enExample)
MX (1) MX2007007098A (enExample)
PE (1) PE20060736A1 (enExample)
PL (1) PL1828172T3 (enExample)
PT (1) PT1828172E (enExample)
RU (1) RU2007126761A (enExample)
TW (1) TW200635921A (enExample)
WO (1) WO2006063763A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
EP2327693B9 (en) 2007-12-14 2012-10-24 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
KR101276530B1 (ko) * 2009-02-24 2013-06-18 머크 캐나다 인크. Ｃｒｔｈ２ 수용체 길항제로서의 인돌 유도체
WO2011079007A1 (en) 2009-12-23 2011-06-30 Ironwood Pharmaceuticals, Inc. Crth2 modulators
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
WO2011117184A1 (de) 2010-03-24 2011-09-29 Bayer Cropscience Ag Fludioxonil-derivate
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012078210A1 (en) * 2010-12-08 2012-06-14 Ironwood Pharmaceuticals, Inc. Crth2 modulators and preparation thereof
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
WO2013155422A1 (en) * 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
ES2461415B1 (es) * 2012-10-16 2015-03-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados funcionalizados e inmunorreactivos para el fungicida fludioxonil
CN103553990B (zh) * 2013-11-08 2016-01-20 苏州诚和医药化学有限公司 用卤素卤化合成2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法
CN103588686B (zh) * 2013-11-08 2016-01-20 苏州诚和医药化学有限公司 一种用卤素卤化制备2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法
CN103553991B (zh) * 2013-11-08 2016-01-20 苏州诚和医药化学有限公司 一种制备2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法
TWI649321B (zh) 2014-03-17 2019-02-01 瑞士商愛杜西亞製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
CN108164502B (zh) * 2018-03-06 2021-04-13 苏州华一新能源科技有限公司 1,3-丙烷磺酸内酯的制备方法
CN112602714B (zh) * 2020-12-23 2021-11-16 华南农业大学 一类咯菌腈羧酸衍生物在用于植物维管组织靶向药剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182737A3 (de) * 1984-10-16 1986-10-08 Ciba-Geigy Ag 3-Phenylpyrrolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
EP0386681A1 (de) * 1989-03-08 1990-09-12 Ciba-Geigy Ag 3-Aryl-4-cyano-pyrrol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende mikrobiozide Mittel
US20050101657A1 (en) * 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
JP4316232B2 (ja) * 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CA2568742A1 (en) * 2004-05-29 2005-12-08 7Tm Pharma A/S Substituted thiazoleacetic as crth2 ligands

Also Published As

Publication number Publication date
RU2007126761A (ru) 2009-01-27
KR20070087605A (ko) 2007-08-28
AU2005315881A1 (en) 2006-06-22
AU2005315881B2 (en) 2009-09-24
PT1828172E (pt) 2010-02-17
ATE449772T1 (de) 2009-12-15
CN101072773B (zh) 2011-01-19
CA2587934A1 (en) 2006-06-22
TW200635921A (en) 2006-10-16
JP2008523130A (ja) 2008-07-03
PL1828172T3 (pl) 2010-05-31
MX2007007098A (es) 2007-06-22
DE602005017935D1 (de) 2010-01-07
US20100087432A1 (en) 2010-04-08
WO2006063763A1 (en) 2006-06-22
CN101072773A (zh) 2007-11-14
EP1828172A1 (en) 2007-09-05
EP1828172B1 (en) 2009-11-25
PE20060736A1 (es) 2006-09-08
BRPI0518607A2 (pt) 2008-11-25
GB0427381D0 (en) 2005-01-19
ES2335519T3 (es) 2010-03-29
GT200500360A (es) 2006-08-07
AU2005315881C1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
AR052266A1 (es) Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos
AR109033A2 (es) Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
UY32682A (es) "derivados de 1h-imidazo-[4,5-c]-quinolinona"
SMT201700006B (it) Analoghi della triazina e uso di essi come agenti terapeutici e sonde diagnostiche
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
ECSP11011327A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
MX2015004771A (es) Metodos para tratar cancer.
CL2007003187A1 (es) Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
CY1110425T1 (el) Συνεργεια των gos και της πολυφρουκτοζης
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
AR082844A1 (es) Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos
AR083268A1 (es) Conjugado de naloxol-peg cristalino
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
EP1792899A4 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO DERIVATIVES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal